Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Justin Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Shira Dinner, MD, Sangmin Lee, MD, Karen Seiter, MD, Thomas Prebet, MD PhD, Gary J. Schiller, MD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Hagop M. Kantarjian, MD, Patrick Kelly, MD, Ping Li, PhD, Jennifer Sweeney, Courtney Watson, Hesham Mohamed, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2018-99-114263

Published: 2018

Journal Articles

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States

Karen Seiter, MD, Dominick Latremouille-Viau, Annie Guerin, MS, Briana Ndife, MPH, Karen Habucky, PhD, George J Joseph, BPharm, MS, PhD, Irina Pivneva, PhD, Patrick Gagnon-Sanschagrin, MS, Derek H Tang, BSPharm, PhD

Blood (2017) 130 (Supplement 1): 3391.

https://doi.org/10.1182/blood.V130.Suppl_1.3391.3391

Published: 2017

Journal Articles

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Blood (2017) 130 (Supplement 1): 891.

https://doi.org/10.1182/blood.V130.Suppl_1.891.891

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD

Blood (2016) 128 (22): 2843.

https://doi.org/10.1182/blood.V128.22.2843.2843

Published: 2016

Journal Articles

CLAG-Based Induction Therapy in Previously Untreated High Risk AML Patients

Karen Seiter, MD, Stephanie Germani, FNP, Julie Martin, FNP, Rosemarie Raffa, FNP, Michele Reilly, ANP, Nasir Ahmed, MD, Paul Baskind, Delong Liu, MD PhD

Blood (2015) 126 (23): 4892.

https://doi.org/10.1182/blood.V126.23.4892.4892

Published: 2015

Journal Articles

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Blood (2015) 126 (23): 2580.

https://doi.org/10.1182/blood.V126.23.2580.2580

Published: 2015

Journal Articles

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Blood (2014) 124 (21): 116.

https://doi.org/10.1182/blood.V124.21.116.116

Published: 2014

Journal Articles

A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents

Guillermo Garcia-Manero, MD, Selina M Luger, MD, Stuart Goldberg, MD, Jessica K Altman, MD, Martha Arellano, MD, Meir Wetzler, MD, Karen Seiter, MD, Judy Chiao, MD, Hagop M Kantarjian, MD

Blood (2013) 122 (21): 2752.

https://doi.org/10.1182/blood.V122.21.2752.2752

Published: 2013

Journal Articles

Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine

Karen Yee, MD, Giovanni Martinelli, MD, Sarit Assouline, MD, Margaret Kasner, MD, Norbert Vey, MD PhD, Kevin R. Kelly, MD, PhD, Mark W. Drummond, PhD, FRCPath, MB, CHB, Michael Dennis, FRCP, FRCPath, Karen Seiter, MD, Steven Blotner, PhD, Lori Jukofsky, Steven Middleton, PhD, Jianguo Zhi, PhD, Gong Chen, PhD, Hua Zhong, PhD, Gwen Nichols, MD

Blood (2013) 122 (21): 498.

https://doi.org/10.1182/blood.V122.21.498.498

Published: 2013

Journal Articles

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

Farhad Ravandi, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, PhD, Stuart L. Goldberg, MD, Meir Wetzler, MD, Parameswaran Venugopal, MD, Karen Seiter, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2630.

https://doi.org/10.1182/blood.V120.21.2630.2630

Published: 2012

Journal Articles

High Response Rate and Prolonged Survival in Patients with Primary Refractory Acute Myelogenous Leukemia Treated with Decitabine Salvage Therapy

Ana Fernandez, MD, Dhaval Shah, MD, MBBS, Delong Liu, MD, PhD, Nasir Ahmed, MD, Elizabeth Lulaj, MD, Karen Seiter, MD

Blood (2011) 118 (21): 4280.

https://doi.org/10.1182/blood.V118.21.4280.4280

Published: 2011

Journal Articles

Marqibo ® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) In Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)

Jeffrey A Silverman, PhD, Walter E. Aulitzky, MD, John Lister, MD, Lori Maness, M.D., Gary J Schiller, MD, Karen Seiter, MD, Scott Smith, MD, PhD, FACP, Wendy Stock, MD, Dina Ben Yehuda, Steven R. Deitcher, MD

Blood (2010) 116 (21): 2142.

https://doi.org/10.1182/blood.V116.21.2142.2142

Published: 2010

Journal Articles

Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.

Susan O'Brien, MD, Gary Schiller, Lloyd E. Damon, MD, John Lister, MD, Farhad Ravandi, MD, Dan Douer, MD, Aisha Masood, MD, Dina Ben-Yehuda, Jacob M. Rowe, MD, Nicola Gökbuget, Walter Aulitzky, Wendy Stock, MD, Steven Coutre, MD, Leonard Heffner, MD, Melissa L. Larson, MD, Karen Seiter, MD, Anne E Hagey, MD, Steven R. Deitcher, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 3088.

https://doi.org/10.1182/blood.V114.22.3088.3088

Published: 2009

Journal Articles

Rasburicase Effectively Lowers Serum Uric Acid Levels in High Risk, Poor Performance Status Patients with Hematologic Malignancies

Doris Ponce, MD, Delong Liu, MD, PhD, Muhammad Rasul, MD, Nasir Ahmed, MD, Marie Dimicco, PhD, Karen Seiter, MD

Blood (2008) 112 (11): 4012.

https://doi.org/10.1182/blood.V112.11.4012.4012

Published: 2008

Journal Articles

Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome : Results of a Randomized Comparative Phase III Study.

Jorge Cortes, MD, Karen Seiter, MD, Richard Thomas Maziarz, MD, Meir Wetzler, MD, Michael Craig, MD, Jeffrey Matous, Selina Luger, MD, Bimalangshu Dey, MD, Gary J. Schiller, MD, FACP, Dat Pham, MD, Camille N. Abboud, MD, FACP, Muthuswamy Krishnamurthy, MD, Archie Brown, Jr., MD, Joseph O. Moore, MD

Blood (2008) 112 (11): 919.

https://doi.org/10.1182/blood.V112.11.919.919

Published: 2008

Journal Articles

Emerging Epidemics of Babesiosis in Hematology Consultation at a University Hospital.

Srilatha Hosur, MD, Delong Liu, MD, PHD, Karen Seiter, MD, John Nelson, MD, Maria Aguero-Rosenfeld, MD, Sergey Brodsky, MD, PHD, Tauseef Ahmed, MD, Gary Wormser, MD

Blood (2007) 110 (11): 3859.

https://doi.org/10.1182/blood.V110.11.3859.3859

Published: 2007

Journal Articles

Ciprofloxacin-Induced G 2 Arrest and Apoptosis in TK6 Lymphoblastoid Cells Is Not Dependent on Double-Strand Break Formation.

Dorota Halicka, MD, PhD, Daniel J. Smart, PhD, Karen Seiter, MD, Frank Traganos, PhD, Zbigniew Darzynkiewicz, MD,PhD, Gary M. Williams, MD

Blood (2007) 110 (11): 4094.

https://doi.org/10.1182/blood.V110.11.4094.4094

Published: 2007

Journal Articles

Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.

Doris Ponce, MD, Sreedhar Katragadda, MD, Delong Liu, MD.PhD, Muhammad Rasul, MD, Nasir Ahmed, MD, Tauseef Ahmed, MD, Karen Seiter, MD

Blood (2007) 110 (11): 4383.

https://doi.org/10.1182/blood.V110.11.4383.4383

Published: 2007

Journal Articles

Phase I Study of Temozolomide and Cisplatin in Patients with Acute Leukemia.

Sreedhar Katragadda, MD, Delong Liu, MD PhD, Dorota Halicka, PhD, Sanford Kempin, MD, Nasir Ahmed, MD, Tauseef Ahmed, MD, Karen Seiter, MD

Blood (2006) 108 (11): 4542.

https://doi.org/10.1182/blood.V108.11.4542.4542

Published: 2006

NARROW

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

CLAG-Based Induction Therapy in Previously Untreated High Risk AML Patients

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents

Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

High Response Rate and Prolonged Survival in Patients with Primary Refractory Acute Myelogenous Leukemia Treated with Decitabine Salvage Therapy

Marqibo ® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) In Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)

Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.

Rasburicase Effectively Lowers Serum Uric Acid Levels in High Risk, Poor Performance Status Patients with Hematologic Malignancies

Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome : Results of a Randomized Comparative Phase III Study.

Emerging Epidemics of Babesiosis in Hematology Consultation at a University Hospital.

Ciprofloxacin-Induced G 2 Arrest and Apoptosis in TK6 Lymphoblastoid Cells Is Not Dependent on Double-Strand Break Formation.

Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.

Phase I Study of Temozolomide and Cisplatin in Patients with Acute Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only